Back

Back

Surveillance Monitoring for ART Toxicities (SMARTT) A Study of the National Institutes of Health

SMARTT

The Surveillance Monitoring for ART Toxicities (SMARTT) Study evaluated the long-term safety of antiretroviral (ARV) medications taken during pregnancy among women living with HIV (WLHIV) and their children born without HIV. The PHACS SMARTT study is the largest study of pregnant WLHIV in the United States, and one of the only large studies in the world to follow children born to WLHIV beyond infancy.

Loading…

Protocol Chairs

Photo of Ellen Chadwick

Ellen Chadwick, MD

Professor, Pediatrics (Infectious Diseases)

Northwestern Feinberg School of Medicine

EGChadwick@luriechildrens.org

Photo of Paige Williams

Paige Williams, PhD

Senior Lecturer on Biostatistics

Harvard T.H. Chan School of Public Health

paige@sdac.harvard.edu

DASH Datasets

Surveillance Monitoring for ART Toxicities Study in HIV-uninfected Children Born to HIV-infected Women, PH100 (SMARTT)

The PHACS Surveillance Monitoring for ART Toxicities (SMARTT) Study was designed to identify potential adverse effects of ARV exposures in infants born to women with HIV infection, and to evaluate associations with ARV combinations and specific ARV drugs in order to help inform treatment guidelines for HIV-infected pregnant women. SMARTT follows two cohorts of HIV- and ART-exposed but uninfected children: the Static and Dynamic cohorts. Domains of interest include birth outcomes, growth, metabolic, cardiac, neurological, neurodevelopmental, behavior, language, and hearing. Biospecimens are available.

Source Repository

DASH

Date Released

April 5, 2019